Bromazepam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Bromazepam: From Anxiety Treatment to Migraine Disorder
One-Sentence Summary
Bromazepam is a benzodiazepine that acts on GABA-A receptors. It is marketed in Singapore as Lexotan tablets, and published studies show it works for generalized anxiety. The TxGNN model's top prediction is migraine disorder, but it is a model prediction only, with 0 clinical trials and 0 publications supporting it. The most evidence-supported prediction for this drug is anxiety, which is effectively an established use rather than true repurposing, with 1 clinical trial and 20 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records (published studies support generalized anxiety) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.06% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Bromazepam is known to be a benzodiazepine that enhances GABA-A receptor-mediated inhibition. Its efficacy in anxiety is established, and mechanistically it might be applicable to migraine only through speculative routes, such as muscle relaxation or anxiolysis in stress-triggered attacks.
The migraine prediction is weak. Benzodiazepines are not an established migraine therapy, and dependence and medication-overuse headache argue against their use. The high TxGNN score is a model output, likely reflecting graph proximity between related migraine terms (the model also ranked "migraine with brainstem aura" and "migraine with or without aura, susceptibility to" highly) rather than independent drug-specific evidence.
Other predictions fall into three groups:
- Established use: Anxiety (rank 6) has the strongest evidence, including randomized, placebo-controlled trials in generalized anxiety.
- Plausible by class, but indirect: Insomnia (rank 3) and alcohol withdrawal delirium (rank 7) are plausible through GABA-A modulation, but no bromazepam-specific efficacy studies were found.
- Likely knowledge-graph artifacts: Atrophoderma vermiculata, ulerythema ophryogenesis and tendinitis have no credible mechanism or evidence. Dysthymic disorder is not supported either, since benzodiazepines are not recommended as antidepressant therapy.
Clinical Trial Evidence
For the top prediction (migraine disorder): Currently no related clinical trials registered.
For anxiety, the best-supported prediction:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02374567 | Phase 3 | Terminated | 407 | Pharmacovigilance study of adverse drug reactions in elderly gerontopsychiatric inpatients. It addresses safety monitoring, not anxiolytic efficacy, so relevance is indirect. |
Literature Evidence
For the top prediction (migraine disorder): Currently no related literature available.
For anxiety, the most relevant publications are below. Insomnia has only indirect literature, with no controlled bromazepam efficacy study.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6132936 | 1983 | RCT | J Clin Psychopharmacol | In 48 patients with generalized anxiety, bromazepam (18 mg/day) and diazepam were both superior to placebo. Bromazepam was more effective than diazepam on the somatic anxiety factor. |
| 1969172 | 1990 | RCT | Psychopharmacology | In 245 general practice patients with generalized anxiety, bromazepam was significantly superior to placebo. It also outperformed chlorprothixene on Hamilton Anxiety score reduction. |
| 13969 | 1977 | RCT | Dis Nerv Syst | Controlled comparison of bromazepam, amitriptyline and placebo in 72 patients with anxiety-depressive neurosis. |
| 2880459 | 1986 | Placebo-controlled study | Acta Psychiatr Scand | In 60 outpatients with generalized anxiety, bromazepam and lorazepam were similar and both superior to placebo. Cognitive impairment was lower with bromazepam. |
| 32039743 | 2020 | Systematic review / network meta-analysis | Acta Neuropsychiatr | Pharmacological treatments for social anxiety disorder in adults. |
| 11801236 | 2002 | Review | Biol Psychiatry | Single trials suggest bromazepam may have efficacy in social anxiety disorder, but SSRIs remain first line. |
| 24409202 | 2014 | Review | Ther Adv Neurol Disord | One randomized controlled study found bromazepam effective for anxiety in Parkinson's disease. |
| 27663828 | 2016 | Case report | Psychiatr Danub | Megadose bromazepam dependence, illustrating the dependence risk of long-term use. |
| 1292648 | 1992 | Case report | Biomed Pharmacother | Oromandibular dystonia after taking bromazepam. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN00382P | LEXOTAN TABLET 3 mg | Tablet | Not stated in the licence record |
| SIN00385P | LEXOTAN TABLET 1.5 mg | Tablet | Not stated in the licence record |
Safety Considerations
Please refer to the package insert for safety information.
Published literature compiled for this report notes that benzodiazepines can cause tolerance and dependence even after short use, with cognitive impairment, falls and traffic accidents linked to chronic use. A case of megadose bromazepam dependence and a case of bromazepam-induced dystonia have been reported.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, migraine disorder, rests only on a model score, with no trials, no literature, and no credible mechanism. Benzodiazepines are not an established migraine therapy, and dependence and medication-overuse headache are concerns. The anxiety prediction is well supported (L1) but is an established use, not new repurposing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), and the approved indication text for the two licences
- Mechanism-of-action data from DrugBank
- Any clinical or mechanistic evidence for bromazepam in migraine before further consideration
- For insomnia and alcohol withdrawal, bromazepam-specific controlled studies, compared against established agents
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.